FIELD: medicine.
SUBSTANCE: invention claims 19-nor-D-homosteroids with mixed androgenic/progestagenic profile and oral activity, preventing bone mineral density (BMD) loss in trabecular bones, with zero liver toxicity, with structure of the formula (I) 
, where R1 is O, R2 is methyl or ethyl, and R3 is hydrogen.
EFFECT: improved efficiency of composition and treatment method.
9 cl, 3 ex, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS, SET, ANDROGENIC COMPOSITION | 2000 |
|
RU2242479C2 |
| STEROID COMPOUND, ITS USING AND TREATMENT METHOD | 2002 |
|
RU2294332C2 |
| COMPOUND (α)-7-METHYL-17-[(1-OXOUNDECYL)OXY]-ESTR-4-ENE-3-ONE, PHARMACEUTICAL COMPOSITION, SET FOR MALE CONTRACEPTION | 1999 |
|
RU2216546C2 |
| 15β-SUBSTITUTED STEROIDS WITH SELECTIVE OESTROGENIC ACTIVITY | 2005 |
|
RU2386637C2 |
| CONTRACEPTIVE INJECTION OF OIL SOLUTION INJECTED INDEPENDENTLY | 2003 |
|
RU2328289C2 |
| METHOD FOR PREPARING 7α-METHYLSTEROIDS, COMPOUND | 2003 |
|
RU2305105C2 |
| OESTROGEN RECEPTOR LIGANDS AND METHODS OF USING THEM | 2010 |
|
RU2543339C2 |
| STEROID COMPOUND, METHODS OF ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION | 1998 |
|
RU2182153C2 |
| USE OF NOVEL ETHONOGESTREL ESTERS | 2003 |
|
RU2322986C2 |
| DERIVATIVES OF ESTRA-1,3,5(10)-TRIENE, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION | 1995 |
|
RU2139885C1 |
